These analyses, together with our additional subgroup analyses by metastatic site location or number and in patients with TP53-mutated tumors, HER2-low tumor expression, or different ESR1 mutation variants, suggest that elacestrant can be an option for patients with endocrine-sensitive tumors. This evidence concerns the gene ERBB2 and neoplasm.